{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:18:50Z","timestamp":1792801130023,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T00:00:00Z","timestamp":1636675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T00:00:00Z","timestamp":1636675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"new zealand equine trust","award":["RM 20461"],"award-info":[{"award-number":["RM 20461"]}],"id":[{"id":"https:\/\/ror.org\/02hqt0c96","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mesenchymal stromal cells (MSCs) are believed to be hypoimmunogeneic with potential use for allogeneic administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Bone marrow was harvested from Connemara (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091), Standardbred (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096), and Thoroughbred (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093) horses. MSCs were grouped by their level of expression of major histocompatibility factor II (MHC II). MSCs were then sub-grouped by those MSCs derived from universal blood donor horses. MSCs were isolated and cultured using media containing fetal bovine serum until adequate numbers were acquired. The MSCs were cultured in xenogen-free media for 48\u00a0h prior to use and during all assays. Autologous and allogeneic MSCs were then directly co-cultured with responder leukocytes from the Connemara horse in varying concentrations of MSCs to leukocytes (1:1, 1:10, and 1:100). MSCs were also cultured with complement present and heat-inactivated complement to determine whether complement alone would decrease MSC viability. MSCs underwent haplotyping of their equine leukocyte antigen (ELA) to determine whether the MHC factors were matched or mismatched between the donor MSCs and the responder leukocytes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All allogeneic MSCs were found to be ELA mismatched with the responder leukocytes. MHC II-low and universal blood donor MSCs caused no peripheral blood mononuclear cell (PBMC) proliferation, no increase in B cells, and no activation of CD8 lymphocytes. Universal blood donor MSCs stimulated a significant increase in the number of T regulatory cells. Neutrophil interaction with MSCs showed that universal blood donor and MHC II-high allogeneic MSCs at the 6\u00a0h time point in co-culture caused greater neutrophil activation than the other co-culture groups. Complement-mediated cytotoxicity did not consistently cause MSC death in cultures with active complement as compared to those with inactivated complement. Gene expression assays revealed that the universal blood donor group and the MHC II-low MSCs were more metabolically active both in the anabolic and catabolic gene categories when cultured with allogeneic lymphocytes as compared to the other co-cultures. These upregulated genes included CD59, FGF-2, HGF, IDO, IL-10, IL-RA, IL-2, SOX2, TGF-\u03b21, ADAMSTS-4, ADAMSTS-5, CCL2, CXCLB\/IL-8, IFN\u03b3, IL-1\u03b2, and TNF\u03b1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MHC II-low MSCs are the most appropriate type of allogeneic MSC to prevent activation of the innate and cell-mediated component of the adaptive immune systems and have increased gene expression as compared to other allogeneic MSCs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13287-021-02624-y","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T07:02:55Z","timestamp":1636700575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Immune response to allogeneic equine mesenchymal stromal cells"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1634-5540","authenticated-orcid":false,"given":"J. Lacy","family":"Kamm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie A.","family":"Parlane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica K.","family":"Gee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Wayne","family":"McIlwraith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,12]]},"reference":[{"issue":"1","key":"2624_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/cyto.b.20063","volume":"67","author":"E Ahmad","year":"2005","unstructured":"Ahmad E, Kingma DW, Jaffe ES, Schrager JA, Janik J, Wilson W, Stetler-Stevenson M. Flow cytometric immunophenotypic profiles of mature gamma delta T-cell malignancies involving peripheral blood and bone marrow. Cytometry B Clin Cytom. 2005;67(1):6\u201312.","journal-title":"Cytometry B Clin Cytom"},{"issue":"5","key":"2624_CR2","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/imcb.12024","volume":"96","author":"S Alagesan","year":"2018","unstructured":"Alagesan S, Sanz-Nogu\u00e9s C, Chen X, Creane M, Ritter T, Ceredig R, O\u2019Brien T, Griffin MD. Anti-donor antibody induction following intramuscular injections of allogeneic mesenchymal stromal cells. Immunol Cell Biol. 2018;96(5):536\u201348. https:\/\/doi.org\/10.1111\/imcb.12024.","journal-title":"Immunol Cell Biol"},{"issue":"8","key":"2624_CR3","doi-asserted-by":"publisher","first-page":"e104662","DOI":"10.1371\/journal.pone.0104662","volume":"9","author":"PR Amable","year":"2014","unstructured":"Amable PR, Teixeira MV, Carias RB, Granjeiro JM, Borojevic R. Mesenchymal stromal cell proliferation, gene expression and protein production in human platelet-rich plasma-supplemented media. PLoS ONE. 2014;9(8):e104662. https:\/\/doi.org\/10.1371\/journal.pone.0104662.","journal-title":"PLoS ONE"},{"key":"2624_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12917-016-0692-x","volume":"12","author":"N Ardanaz","year":"2016","unstructured":"Ardanaz N, V\u00e1zquez FJ, Romero A, Remacha AR, Barrachina L, Sanz A, Ranera B, Vitoria A, Albareda J, Prades M, Zaragoza P, Mart\u00edn-Burriel I, Rodellar C. Inflammatory response to the administration of mesenchymal stem cells in an equine experimental model: effect of autologous, and single and repeat doses of pooled allogeneic cells in healthy joints. BMC Vet Res. 2016;12:65.","journal-title":"BMC Vet Res"},{"issue":"8","key":"2624_CR5","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1002\/sctm.17-0035","volume":"6","author":"B Arzi","year":"2017","unstructured":"Arzi B, Clark KC, Sundaram A. Therapeutic efficacy of fresh, allogeneic mesenchymal stem cells for severe refractory feline chronic gingivostomatitis. Stem Cells Transl Med. 2017;6(8):1710\u201322. https:\/\/doi.org\/10.1002\/sctm.17-0035.","journal-title":"Stem Cells Transl Med"},{"key":"2624_CR6","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.exphem.2009.01.005","volume":"37","author":"S Asari","year":"2009","unstructured":"Asari S, Itakura S, Ferreri K, Liu CP, Kuroda Y, Kandeel F, Mullen Y. Mesenchymal stem cells suppress B-cell terminal differentiation. Exp Hematol. 2009;37:604.","journal-title":"Exp Hematol"},{"issue":"1","key":"2624_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13287-020-1571-8","volume":"11","author":"L Barrachina","year":"2020","unstructured":"Barrachina L, Cequier A, Romero A, Vitoria A, Zaragoza P, Vazquez FJ, et al. Allo-antibody production after intraarticular administration of mesenchymal stem cells (MSCs) in an equine osteoarthritis model: effect of repeated administration, MSC inflammatory stimulation, and equine leukocyte antigen (ELA) compatibility. Stem Cell Res Ther. 2020;11(1):52.","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"2624_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/evj.12647","volume":"49","author":"AK Berglund","year":"2017","unstructured":"Berglund AK, Schnabel LV. Allogeneic major histocompatibility complex-mismatched equine bone marrow-derived mesenchymal stem cells are targeted for death by cytotoxic anti-major histocompatibility complex antibodies. Equine Vet J. 2017;49(4):539\u201344. https:\/\/doi.org\/10.1111\/evj.12647.","journal-title":"Equine Vet J"},{"issue":"3","key":"2624_CR9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.molimm.2013.05.221","volume":"56","author":"G Bergseth","year":"2013","unstructured":"Bergseth G, Ludviksen JK, Kirschfink M, Giclas PC, Nilsson B, Mollnes TE. An international serum standard for application in assays to detect human complement activation products. Mol Immunol. 2013;56(3):232\u20139. https:\/\/doi.org\/10.1016\/j.molimm.2013.05.221.","journal-title":"Mol Immunol"},{"issue":"2","key":"2624_CR10","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jcyt.2017.09.013","volume":"20","author":"LR Braid","year":"2018","unstructured":"Braid LR, Wood CA, Wiese DM, Ford BN. Intramuscular administration potentiates extended dwell time of mesenchymal stromal cells compared to other routes. Cytotherapy. 2018;20(2):232\u201344. https:\/\/doi.org\/10.1016\/j.jcyt.2017.09.013.","journal-title":"Cytotherapy"},{"issue":"1","key":"2624_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13287-018-0840-2","volume":"9","author":"JM Cassano","year":"2018","unstructured":"Cassano JM, Schnabel LV, Goodale MB, Fortier LA. Inflammatory licensed equine MSCs are chondroprotective and exhibit enhanced immunomodulation in an inflammatory environment. Stem Cell Res Ther. 2018;9(1):82. https:\/\/doi.org\/10.1186\/s13287-018-0840-2.","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"2624_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3109\/14653249.2010.536213","volume":"13","author":"DD Carrade","year":"2011","unstructured":"Carrade DD, Owens SD, Galuppo LD, et al. Clinicopathologic findings following intra-articular injection of autologous and allogeneic placentally derived equine mesenchymal stem cells in horses. Cytotherapy. 2011;13(4):419\u201330. https:\/\/doi.org\/10.3109\/14653249.2010.536213.","journal-title":"Cytotherapy"},{"key":"2624_CR13","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.3389\/fimmu.2019.01288","volume":"10","author":"L Carreras-Planella","year":"2019","unstructured":"Carreras-Planella L, Mongui\u00f3-Tortajada M, Borr\u00e0s FE, Franquesa M. Immunomodulatory effect of MSC on B cells is independent of secreted extracellular vesicles. Front Immunol. 2019;10:2413. https:\/\/doi.org\/10.3389\/fimmu.2019.01288.","journal-title":"Front Immunol"},{"issue":"1","key":"2624_CR14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/evj.13136","volume":"52","author":"AC Colbath","year":"2020","unstructured":"Colbath AC, Dow SW, Hopkins LS, Phillips JN, McIlwraith CW, Goodrich LR. Allogeneic vs. autologous intra-articular mesenchymal stem cell injection within normal horses: clinical and cytological comparisons suggest safety. Equine Vet J. 2020;52(1):144\u201351.","journal-title":"Equine Vet J"},{"key":"2624_CR15","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1093\/ndt\/gfm740","volume":"23","author":"P Comoli","year":"2008","unstructured":"Comoli P, Ginevri F, Maccario R, Avanzini A, Marconi MA, Groff M, Cometa A, Cioni AM, Porretti L, Barberi W, Frassoni F, Locatelli F. Human mesenchymal stem cells inhibit anti-body production induced in vitro by allostimulation. Nephrol Dial Transplant. 2008;23:1196.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"2624_CR16","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2217\/rme.15.14","volume":"10","author":"C Consentius","year":"2015","unstructured":"Consentius C, Reinke P, Volk HD. Immunogenicity of allogeneic mesenchymal stromal cells: what has been seen in vitro and in vivo? Regen Med. 2015;10(3):305\u201315. https:\/\/doi.org\/10.2217\/rme.15.14.","journal-title":"Regen Med"},{"issue":"1","key":"2624_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/nyas.13364","volume":"1417","author":"P Contreras-Kallens","year":"2018","unstructured":"Contreras-Kallens P, Terraza C, Oyarce K, Gajardo T, Campos-Mora M, Barroilhet MT, \u00c1lvarez C, Fuentes R, Figueroa F, Khoury M, Pino-Lagos K. Mesenchymal stem cells and their immunosuppressive role in transplantation tolerance. Ann N Y Acad Sci. 2018;1417(1):35\u201356. https:\/\/doi.org\/10.1111\/nyas.13364.","journal-title":"Ann N Y Acad Sci"},{"key":"2624_CR18","doi-asserted-by":"publisher","first-page":"R35","DOI":"10.1186\/ar2640","volume":"11","author":"JC de Grauw","year":"2009","unstructured":"de Grauw JC, van de Lest CHA, van Weeren PR. Inflammatory mediators and cartilage biomarkers in synovial fluid after a single inflammatory insult: a longitudinal experimental study. Res Ther. 2009;11:R35. https:\/\/doi.org\/10.1186\/ar2640.","journal-title":"Res Ther"},{"issue":"3","key":"2624_CR19","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1177\/0363546519899087","volume":"48","author":"ML Delco","year":"2020","unstructured":"Delco ML, Goodale M, Talts JF, Pownder SL, Koff MF, Miller AD, Nixon B, Bonassar LJ, Lundgren-\u00c5kerlund E, Fortier LA. Integrin \u03b110\u03b21-selected mesenchymal stem cells mitigate the progression of osteoarthritis in an equine Talar impact model. Am J Sports Med. 2020;48(3):612\u201323. https:\/\/doi.org\/10.1177\/0363546519899087.","journal-title":"Am J Sports Med"},{"key":"2624_CR20","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1182\/blood.V99.10.3838","volume":"99","author":"M Di Nicola","year":"2002","unstructured":"Di Nicola M, Carlo-Stella C, Magni M. Human bone marrow stromal cells suppress Tlymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99:3838\u201343.","journal-title":"Blood"},{"key":"2624_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/scrt75","volume":"2","author":"MM Duffy","year":"2011","unstructured":"Duffy MM, Ritter T, Ceredig R, Griffin MD. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther. 2011;2:34.","journal-title":"Stem Cell Res Ther"},{"key":"2624_CR22","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1002\/eji.201141499","volume":"41","author":"MM Duffy","year":"2011","unstructured":"Duffy MM, Pindjakova J, Hanley SA, McCarthy C, Weidhofer GA, Sweeney EM. Mesenchymal stem cell inhibition of T-helper 17 cell- differentiation is triggered by cell\u2013cell contact and mediated by prostaglandin E2 via the EP4 receptor. Eur J Immunol. 2011;41:2840\u201351.","journal-title":"Eur J Immunol"},{"key":"2624_CR23","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fimmu.2012.00212","volume":"3","author":"M Franquesa","year":"2012","unstructured":"Franquesa M, Hoogduijn MJ, Bestard O, Grinyo JM. Immunomodulatory effect of mesenchymal stem cells on B cells. Front Immunol. 2012;3:212.","journal-title":"Front Immunol"},{"issue":"12","key":"2624_CR24","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1097\/TP.0b013e3181fed001","volume":"90","author":"W Ge","year":"2010","unstructured":"Ge W, Jiang J, Arp J, Liu W, Garcia B, Wang H. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation. 2010;90(12):1312\u201320. https:\/\/doi.org\/10.1097\/TP.0b013e3181fed001.","journal-title":"Transplantation"},{"key":"2624_CR25","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1111\/j.1600-6143.2009.02721.x","volume":"9","author":"W Ge","year":"2009","unstructured":"Ge W, Jiang J, Baroja ML, Arp J, Zassoko R, Liu W, Bartholomew A, Garcia B, Wang H. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant. 2009;9:1760.","journal-title":"Am J Transplant"},{"key":"2624_CR26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/978-1-62703-200-1_13","volume-title":"Mesenchymal stem cell therapy","author":"M Gnecchi","year":"2013","unstructured":"Gnecchi M, Cervio E. Mesenchymal stem cell therapy for heart disease. In: Chase LG, Vemuri MC, editors. Mesenchymal stem cell therapy. Totowa: Humana Press; 2013. p. 241."},{"key":"2624_CR27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/icb.2012.67","volume":"91","author":"MD Griffin","year":"2013","unstructured":"Griffin MD, Ryan AE, Alagesan S, Lohan P, Treacy O, Ritter T. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far? Immunol Cell Biol. 2013;91:40\u201351.","journal-title":"Immunol Cell Biol"},{"issue":"3","key":"2624_CR28","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/j.1365-2567.2011.03489.x","volume":"134","author":"E Hamza","year":"2011","unstructured":"Hamza E, Gerber V, Steinbach F, Marti E. Equine CD4(+) CD25(high) T cells exhibit regulatory activity by close contact and cytokine-dependent mechanisms in vitro. Immunology. 2011;134(3):292\u2013304. https:\/\/doi.org\/10.1111\/j.1365-2567.2011.03489.x.","journal-title":"Immunology"},{"key":"2624_CR29","volume-title":"Equine anesthesia: monitoring and emergency therapy","author":"J Hardy","year":"2009","unstructured":"Hardy J. Venous and arterial catheterization and fluid therapy. In: Muir WW, Hubbell JA, editors. Equine anesthesia: monitoring and emergency therapy. 2nd ed. Missouri: Mosby Elsevier; 2009.","edition":"2"},{"issue":"7","key":"2624_CR30","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2460\/ajvr.78.7.867","volume":"78","author":"JA Hill","year":"2017","unstructured":"Hill JA, Cassano JM, Goodale MB, Fortier LA. Antigenicity of mesenchymal stem cells in an inflamed joint environment. Am J Vet Res. 2017;78(7):867\u201375. https:\/\/doi.org\/10.2460\/ajvr.78.7.867.","journal-title":"Am J Vet Res"},{"issue":"8","key":"2624_CR31","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41435-0190075-y","volume":"20","author":"CM Holmes","year":"2019","unstructured":"Holmes CM, Violette N, Miller D, Wagner B, Svansson V, Antczak DF. MHC haplotype diversity in Icelandic horses determined by polymorphic microsatellites. Genes Immun. 2019;20(8):660\u201370. https:\/\/doi.org\/10.1038\/s41435-0190075-y.","journal-title":"Genes Immun"},{"issue":"9","key":"2624_CR32","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1096\/fj.201600331R","volume":"30","author":"XP Huang","year":"2016","unstructured":"Huang XP, Ludke A, Dhingra S, Guo J, Sun Z, Zhang L, Weisel RD, Li RK. Class II transactivator knockdown limits major histocompatibility complex II expression, diminishes immune rejection, and improves survival of allogeneic bone marrow stem cells in the infarcted heart. FASEB J. 2016;30(9):3069\u201382. https:\/\/doi.org\/10.1096\/fj.201600331R.","journal-title":"FASEB J"},{"issue":"6","key":"2624_CR33","first-page":"3890","volume":"11","author":"MDM Joel","year":"2019","unstructured":"Joel MDM, Yuan J, Wang J, Yan Y, Qian H, Zhang X, Xu W, Mao F. MSC: immunoregulatory effects, roles on neutrophils and evolving clinical potentials. Am J Transl Res. 2019;11(6):3890\u2013904.","journal-title":"Am J Transl Res"},{"issue":"1","key":"2624_CR34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13287-017-0503-8","volume":"8","author":"AJ Joswig","year":"2017","unstructured":"Joswig AJ, Mitchell A, Cummings KJ, Levine GJ, Gregory CA, Smith R 3rd. Repeated intra-articular injection of allogeneic mesenchymal stem cells causes an adverse response compared to autologous cells in the equine model. Stem Cell Res Ther. 2017;8(1):42.","journal-title":"Stem Cell Res Ther"},{"issue":"11","key":"2624_CR35","doi-asserted-by":"publisher","first-page":"e0225161","DOI":"10.1371\/journal.pone.0225161","volume":"14","author":"JL Kamm","year":"2019","unstructured":"Kamm JL, Parlane NA, Riley CB, Gee EK, Dittmer KE, McIlwraith CW. Blood type and breed-associated differences in cell marker expression on equine bone marrow-derived mesenchymal stem cells including major histocompatibility complex class II antigen expression. PLoS ONE. 2019;14(11):e0225161. https:\/\/doi.org\/10.1371\/journal.pone.0225161.","journal-title":"PLoS ONE"},{"issue":"8","key":"2624_CR36","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.2042-3306.2010.00140.x","volume":"42","author":"JL Kamm","year":"2010","unstructured":"Kamm JL, Nixon AJ, Witte TH. Cytokine and catabolic enzyme expression in synovium, synovial fluid and articular cartilage of naturally osteoarthritic equine carpi. Equine Vet J. 2010;42(8):693\u20139. https:\/\/doi.org\/10.1111\/j.2042-3306.2010.00140.x.","journal-title":"Equine Vet J"},{"issue":"13","key":"2624_CR37","doi-asserted-by":"publisher","first-page":"E2598","DOI":"10.1073\/pnas.1617933114","volume":"114","author":"MW Klinker","year":"2017","unstructured":"Klinker MW, Marklein RA, Lo Surdo JL, Wei CH, Bauer SR. Morphological features of IFN-\u03b3-stimulated mesenchymal stromal cells predict overall immunosuppressive capacity. Proc Natl Acad Sci U S A. 2017;114(13):E2598\u2013607. https:\/\/doi.org\/10.1073\/pnas.1617933114.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2624_CR38","doi-asserted-by":"crossref","unstructured":"Li Y, Lin F. Mesenchymal stem cells are injured by complement after their contact with serum. Blood 2012;120: 3436\u20133443.","DOI":"10.1182\/blood-2012-03-420612"},{"issue":"9","key":"2624_CR39","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1038\/mt.2016.142","volume":"24","author":"Y Li","year":"2016","unstructured":"Li Y, Fung J, Lin F. Local inhibition of complement improves mesenchymal stem cell viability and function after administration. Mol Ther. 2016;24(9):1665\u201374. https:\/\/doi.org\/10.1038\/mt.2016.142.","journal-title":"Mol Ther"},{"key":"2624_CR40","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12964-019-0471-y","volume":"17","author":"Y Li","year":"2019","unstructured":"Li Y, Wang W, Yang F. The regulatory roles of neutrophils in adaptive immunity. Cell Commun Signal. 2019;17:147.","journal-title":"Cell Commun Signal"},{"issue":"17","key":"2624_CR41","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1089\/scd.2018.0074","volume":"27","author":"L Mari\u00f1as-Pardo","year":"2018","unstructured":"Mari\u00f1as-Pardo L, Garc\u00eda-Castro J, Rodr\u00edguez-Hurtado I, Rodr\u00edguez-Garc\u00eda MI, N\u00fa\u00f1ez-Naveira L, Hermida-Prieto M. Allogeneic adipose-derived mesenchymal stem cells (Horse Allo 20) for the treatment of osteoarthritis-associated lameness in horses: characterization, safety, and efficacy of intra-articular treatment. Stem Cells Dev. 2018;27(17):1147\u201360. https:\/\/doi.org\/10.1089\/scd.2018.0074.","journal-title":"Stem Cells Dev"},{"key":"2624_CR42","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s13075-015-0851-7","volume":"17","author":"W Merkt","year":"2015","unstructured":"Merkt W, Sturm P, Lasitschka F, Tretter T, Watzl C, Saure D, Hundemer M, Schwenger V, Blank N, Lorenz HM, Cerwenka A. Peripheral blood natural killer cell percentages in granulomatosis with polyangiitis correlate with disease inactivity and stage. Arthritis Res Ther. 2015;17:337. https:\/\/doi.org\/10.1186\/s13075-015-0851-7.","journal-title":"Arthritis Res Ther"},{"key":"2624_CR43","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.rvsc.2015.09.010","volume":"103","author":"JL Mumaw","year":"2015","unstructured":"Mumaw JL, Schmiedt CW, Breidling S, Sigmund A, Norton NA, Thoreson M, Peroni JF, Hurley DJ. Feline mesenchymal stem cells and supernatant inhibit reactive oxygen species production in cultured feline neutrophils. Res Vet Sci. 2015;103:60\u20139. https:\/\/doi.org\/10.1016\/j.rvsc.2015.09.010.","journal-title":"Res Vet Sci"},{"key":"2624_CR44","unstructured":"Murphy KA. The complement system and innate immunity. In: Janeways immunobiology, 8th ed. New York: Garland Science; 2012."},{"key":"2624_CR45","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.4049\/jimmunol.177.4.2080","volume":"177","author":"AJ Nauta","year":"2006","unstructured":"Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE. Mesenchymal stem cells inhibit generation and function of both CD34\u00fe-derived and monocyte-derived dendritic cells. J Immunol. 2006;177:2080\u20137.","journal-title":"J Immunol"},{"key":"2624_CR46","doi-asserted-by":"publisher","unstructured":"Nguyen QT, Jacobsen TD, Chahine NO. Effects of inflammation on multiscale biomechanical properties of cartilaginous cells and tissues. ACS Biomater Sci Eng. 2017;3(11):2644\u20132656. https:\/\/doi.org\/10.1021\/acsbiomaterials.6b00671.","DOI":"10.1021\/acsbiomaterials.6b00671"},{"issue":"10","key":"2624_CR47","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.joca.2013.06.025","volume":"21","author":"CM Peeters","year":"2013","unstructured":"Peeters CM, Leijs MJ, Reijman M, van Osch GJVM, Bos PK. Safety of intra-articular cell-therapy with culture-expanded stem cells in humans: a systematic literature review. Osteoarthr Cartil. 2013;21(10):1465\u201373.","journal-title":"Osteoarthr Cartil"},{"key":"2624_CR48","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13287-015-0053-x","volume":"6","author":"LM Pezzanite","year":"2015","unstructured":"Pezzanite LM, Fortier LA, Antczak DF, Cassano JM, Brosnahan MM, Miller D, Schnabel LV. Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo. Stem Cell Res Ther. 2015;6:54. https:\/\/doi.org\/10.1186\/s13287-015-0053-x.","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"2624_CR49","doi-asserted-by":"publisher","first-page":"e9016","DOI":"10.1371\/journal.pone.0009016","volume":"5","author":"SJ Prasanna","year":"2010","unstructured":"Prasanna SJ, Gopalakrishnan D, Shankar SR, Vasandan AB. Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS ONE. 2010;5(2):e9016. https:\/\/doi.org\/10.1371\/journal.pone.0009016.","journal-title":"PLoS ONE"},{"key":"2624_CR50","doi-asserted-by":"publisher","unstructured":"Proverbio D, Perego R, Baggiani L, Ferrucci F, Zucca E, Nobile F, Spada E. Prevalence of Ca blood type and alloantibodies in a population of horses from Italy. Animals (Basel). 2020;10(7):1179. https:\/\/doi.org\/10.3390\/ani10071179.","DOI":"10.3390\/ani10071179"},{"key":"2624_CR51","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1634\/stemcells.2007-0416","volume":"26","author":"L Raffaghello","year":"2008","unstructured":"Raffaghello L, Bianchi G, Bertolotto M, Montecucco F, Busca A, Dallegri F, Ottonello L, Pistoia V. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells. 2008;26:151\u201362.","journal-title":"Stem Cells"},{"issue":"1","key":"2624_CR52","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/j.1582-4934.2012.01660.x","volume":"17","author":"E Ragni","year":"2013","unstructured":"Ragni E, Vigan\u00f2 M, Rebulla P, Giordano R, Lazzari L. What is beyond a qRT-PCR study on mesenchymal stem cell differentiation properties: how to choose the most reliable housekeeping genes. J Cell Mol Med. 2013;17(1):168\u201380. https:\/\/doi.org\/10.1111\/j.1582-4934.2012.01660.x.","journal-title":"J Cell Mol Med"},{"issue":"2","key":"2624_CR53","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/evj.12414","volume":"48","author":"B Ranera","year":"2016","unstructured":"Ranera B, Antczak D, Miller D, Doroshenkova T, Ryan A, McIlwraith CW, Barry F. Donor-derived equine mesenchymal stem cells suppress proliferation of mismatched lymphocytes. Equine Vet J. 2016;48(2):253\u201360. https:\/\/doi.org\/10.1111\/evj.12414.","journal-title":"Equine Vet J"},{"key":"2624_CR54","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1365-3083.2007.01905.x","volume":"65","author":"I Rasmusson","year":"2007","unstructured":"Rasmusson I, Le Blanc K, Sundberg B, Ringden O. Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol. 2007;65:336\u201343.","journal-title":"Scand J Immunol"},{"issue":"1\u20132","key":"2624_CR55","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.vetimm.2010.11.020","volume":"140","author":"MG Robbin","year":"2011","unstructured":"Robbin MG, Wagner B, Noronha LE, Antczak DF, de Mestre AM. Subpopulations of equine blood lymphocytes expressing regulatory T cell markers. Vet Immunol Immunopathol. 2011;140(1\u20132):90\u2013101. https:\/\/doi.org\/10.1016\/j.vetimm.2010.11.020.","journal-title":"Vet Immunol Immunopathol"},{"issue":"5","key":"2624_CR56","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/sctm.20-0435","volume":"10","author":"AL Rowland","year":"2021","unstructured":"Rowland AL, Miller D, Berglund A, Schnabel LV, Levine GJ, Antczak DF, Watts AE. Cross-matching of allogeneic mesenchymal stromal cells eliminates recipient immune targeting. Stem Cells Transl Med. 2021;10(5):694\u2013710.","journal-title":"Stem Cells Transl Med"},{"issue":"1","key":"2624_CR57","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/scrt402","volume":"5","author":"LV Schnabel","year":"2014","unstructured":"Schnabel LV, Pezzanite LM, Antczak DF, Felippe MJ, Fortier LA. Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro. Stem Cell Res Ther. 2014;5(1):13.","journal-title":"Stem Cell Res Ther"},{"key":"2624_CR58","doi-asserted-by":"publisher","first-page":"650","DOI":"10.4049\/jimmunol.166.1.650","volume":"166","author":"K Shi","year":"2001","unstructured":"Shi K, et al. Lymphoid chemokine B cell-attracting chemokine-1 (CXCL-13) is expressedin germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. J Immunolol. 2001;166:650\u20135.","journal-title":"J Immunolol"},{"key":"2624_CR59","volume-title":"Clinical veterinary advisor: the horse","author":"L Snyder","year":"2012","unstructured":"Snyder L. Blood typing. In: Wilson D, editor. Clinical veterinary advisor: the horse. Pennsylvania: Elsevier Saunders; 2012."},{"issue":"6","key":"2624_CR60","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1111\/jvim.13627","volume":"29","author":"JE Tomlinson","year":"2015","unstructured":"Tomlinson JE, Taberner E, Boston RC, Owens SD, Nolen-Walston RD. Survival time of cross-match incompatible red blood cells in adult horses. J Vet Intern Med. 2015;29(6):1683\u20138. https:\/\/doi.org\/10.1111\/jvim.13627.","journal-title":"J Vet Intern Med"},{"issue":"2","key":"2624_CR61","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/evj.12992","volume":"51","author":"TL Ursini","year":"2019","unstructured":"Ursini TL, Amelse LL, Elkhenany HA, Odoi A, Carter-Arnold JL, Adair HS, Dhar MS. Retrospective analysis of local injection site adverse reactions associated with 230 allogeneic administrations of bone marrow-derived mesenchymal stem cells in 164 horses. Equine Vet J. 2019;51(2):198\u2013205.","journal-title":"Equine Vet J"},{"key":"2624_CR62","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fvets.2015.00049","volume":"2","author":"A Vandenberghe","year":"2015","unstructured":"Vandenberghe A, Broeckx SY, Beerts C, Seys B, Zimmerman M, Verweire I, Suls M, Spaas JH. Tenogenically induced allogeneic mesenchymal stem cells for the treatment of proximal suspensory ligament desmitis in a horse. Front Vet Sci. 2015;2:49. https:\/\/doi.org\/10.3389\/fvets.2015.00049.","journal-title":"Front Vet Sci"},{"issue":"10","key":"2624_CR63","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.1016\/j.transproceed.2009.08.072","volume":"41","author":"Y Wang","year":"2009","unstructured":"Wang Y, Zhang A, Ye Z, Xie H, Zheng S. Bone marrow derived mesenchymal stem cells inhibit acute rejection of rat liver allografts in association with regulatory T-cell expansion. Transplant Proc. 2009;41(10):4352\u20136.","journal-title":"Transplant Proc"},{"issue":"9","key":"2624_CR64","doi-asserted-by":"publisher","first-page":"6832","DOI":"10.1002\/jcp.26436","volume":"233","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Fu L, Liang Y, Guo Z, Wang L, Ma C, Wang H. Exosomes originating from MSCs stimulated with TGF-\u03b2 and IFN-\u03b3 promote Treg differentiation. J Cell Physiol. 2018;233(9):6832\u201340. https:\/\/doi.org\/10.1002\/jcp.26436.","journal-title":"J Cell Physiol"},{"key":"2624_CR65","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12935-020-01193-z","volume":"20","author":"X Zhou","year":"2020","unstructured":"Zhou X, Jin N, Wang F, Chen B. Mesenchymal stem cells: a promising way in therapies of graft-versus-host disease. Cancer Cell Int. 2020;20:114. https:\/\/doi.org\/10.1186\/s12935-020-01193-z.","journal-title":"Cancer Cell Int"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-021-02624-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-021-02624-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-021-02624-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T07:17:57Z","timestamp":1636701477000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-021-02624-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,12]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2624"],"URL":"https:\/\/doi.org\/10.1186\/s13287-021-02624-y","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,12]]},"assertion":[{"value":"3 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was provided by the Massey University Animal Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J. Lacy Kamm and C. Wayne McIlwraith are directors in Advanced Regenerative Therapies\u2014NZ. There are no competing interests for the other authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"570"}}